SCHEMBL1403746

SCHEMBL1403746

OCCOCCOCCS

nearest known ligand 0.69

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.69
KMT2A Q03164 3/20 0.69
TSHR P16473 2/20 0.62
MAPK1 P28482 1/20 0.62
THRB P10828 1/20 0.44
HTT P42858 1/20 0.44
MAPT P10636 1/20 0.44
ALDH1A1 P00352 1/20 0.43
APP P05067 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3909088 1.00 MEN1 (0.69) MEN1KMT2ATSHRMAPK1THRB
SCHEMBL29941787 1.00 MEN1 (0.69) MEN1KMT2ATSHRMAPK1THRB
Tetraethylene Glycol SCHEMBL23524451 1.00 MEN1 (0.69) MEN1KMT2ATSHRMAPK1THRB
SCHEMBL14948191 1.00 MEN1 (0.69) MEN1KMT2ATSHRMAPK1THRB
SCHEMBL61549 0.97
Di(Hydroxyethyl)Ether SCHEMBL1859973 0.97 TSHR (0.67) MEN1KMT2ATSHRMAPK1THRB
Di(Hydroxyethyl)Ether SCHEMBL23524458 0.97 TSHR (0.67) MEN1KMT2ATSHRMAPK1THRB
Ammonia Solution, Strong SCHEMBL28254082 0.94
SCHEMBL28142567 0.94
Tetraethylene Glycol SCHEMBL28289692 0.90 MEN1 (0.73) MEN1KMT2ATSHRMAPK1THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180271423-A1 A BIOSENSOR DEVICE TO DETECT TARGET ANALYTES IN SITU, IN VIVO, AND/OR IN REAL TIME, AND METHODS OF MAKING AND USING THE SAME THE UNIVERSITY OF TOLEDO (US) 2018-09-27 US claimed
EP-1855340-B1 COOLANT COMPOSITION FOR FUEL CELL SHISHIAI KK (JP) 2011-09-07 EP claimed
US-20080251756-A1 COOLANT COMPOSITION FOR FUEL CELL SHISHIAI-KABUSHIKIGAISHA (JP) 2008-10-16 US claimed
EP-1855340-A1 COOLANT COMPOSITION FOR FUEL CELL Shishiai-Kabushikigaisha (JP) 2007-11-14 EP claimed
EP-4731257-A1 CONJUGATES OF SAPONIN AND ANTISENSE OLIGONUCLEOTIDES FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES Sapreme Technologies B.V. (NL) 2026-04-29 EP disclosed
EP-4731261-A1 PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS Sapreme Technologies B.V. (NL) 2026-04-29 EP disclosed
CN-119744179-A Conjugates for targeted therapy 梁碧惠 2025-04-01 CN disclosed
WO-2024261044-A1 PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS SAPREME TECHNOLOGIES B.V. (NL) 2024-12-26 WO disclosed
WO-2024261042-A1 CONJUGATES OF SAPONIN AND ANTISENSE OLIGONUCLEOTIDES FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SAPREME TECHNOLOGIES B.V. (NL) 2024-12-26 WO disclosed
US-20230310618-A1 CONJUGATE FOR TARGETING THERAPY NATIONAL TAIWAN UNIVERSITY (TW) 2023-10-05 US disclosed
CN-108372459-B Chemical mechanical polishing method for tungsten 罗门哈斯电子材料CMP控股股份有限公司 2020-04-21 CN disclosed
US-10286518-B2 Chemical mechanical polishing method for tungsten ROHM AND HAAS ELECTRONIC MATERIALS CMP HOLDINGS, INC. (US) 2019-05-14 US disclosed
WO-2006100188-A9 ANTIWEAR LUBRICANT COMPOSITIONS FOR USE IN COMBUSTION ENGINES CIBA SC HOLDING AG (CH) 2008-02-28 WO disclosed
US-20080039816-A1 Carbohydrate-Encapsulated Quantum Dots for Bilogical Imaging The Government of the United States of America as represented by the Secretary, Department of (US) 2008-02-14 US disclosed
WO-2006127675-A2 NANOPARTICLES AND METHOD TO CONTROL NANOPARTICLE SPACING STATE OF OREGON ACTING BY & THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF OREGON (US) 2006-11-30 WO disclosed
EP-1041100-B1 PROCESSES FOR PRODUCING POLYOXYALKYLENE POLYOL AND PRODUCING DERIVATIVE THEREOF MITSUI CHEMICALS INC (JP) 2006-01-18 EP disclosed
WO-2005093422-A2 CARBOHYDRATE-ENCAPSULATED QUANTUM DOTS FOR BIOLOGICAL IMAGING THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2005-10-06 WO disclosed
WO-2005010481-A2 PREPARATION AND USE OF GOLD GLYCONANOPARTICLES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2005-02-03 WO disclosed
US-6410676-B1 USING PHOSPHAZENIUM CATALYST MITSUI CHEMICALS, INC. (JP) 2002-06-25 US disclosed
EP-1041100-A1 PROCESSES FOR PRODUCING POLYOXYALKYLENE POLYOL AND PRODUCING DERIVATIVE THEREOF Mitsui Chemicals, Inc. (JP) 2000-10-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230310618-A1 CONJUGATE FOR TARGETING THERAPY FOLH1, CD44, SLC10A1 MEN1 439/4885KMT2A 608/4885TSHR 1876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.